We are live on ! Find out more
ITCI

Intra-Cellular Therapies Inc.
ITCI

Delisted

ITCI was delisted on the 1st of April, 2025.

Back to rankings

283 hedge funds and large institutions have $4.38B invested in Intra-Cellular Therapies Inc. in 2022 Q4 according to their latest regulatory filings, with 48 funds opening new positions, 94 increasing their positions, 94 reducing their positions, and 36 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more first-time investments, than exits

New positions opened: 48 | Existing positions closed: 36

14% more capital invested

Capital invested by funds: $3.85B → $4.38B (+$534M)

3% more funds holding

Funds holding: 274 → 283 (+9)

0% more repeat investments, than reductions

Existing positions increased: 94 | Existing positions reduced: 94

14% less funds holding in top 10

Funds holding in top 10: 7 → 6 (-1)

20% less call options, than puts

Call options by funds: $16.9M | Put options by funds: $21M

Holders
283
Holders Change
+9
Holders Change %
+3.28%
% of All Funds
4.55%
Holding in Top 10
6
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-14.29%
% of All Funds
0.1%
New
48
Increased
94
Reduced
94
Closed
36
Calls
$16.9M
Puts
$21M
Net Calls
-$4.11M
Net Calls Change
-$6.53M

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$88.1M
2
JP Morgan Chase
JP Morgan Chase
New York
+$65.7M
3
Citadel Advisors
Citadel Advisors
Florida
+$23.9M
4
BlackRock
BlackRock
New York
+$17.4M
5
Wellington Management Group
Wellington Management Group
Massachusetts
+$12.6M

Top Sellers

Rank Fund Capital Flow
1
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
-$56.7M
2
APM
Avidity Partners Management
Texas
-$45M
3
WA
Wasatch Advisors
Utah
-$25.2M
4
SC
Samlyn Capital
New York
-$25M
5
Point72 Asset Management
Point72 Asset Management
Connecticut
-$23.1M
Name Holding Trade Value Shares
Change 		Change in
Stake
PTC
251
Private Trust Company
Ohio
$10K -$1.4K -28 -13%
FHA
252
First Horizon Advisors
Tennessee
$9.74K – – –
CG
253
Cutler Group
California
$9K +$9.02K +180 New
Carson Wealth (CWM LLC)
254
Carson Wealth (CWM LLC)
Nebraska
$8K +$2.31K +46 +44%
IUHSA
255
Itau Unibanco Holding S.A.
Brazil
$7.99K -$501 -10 -6%
TC
256
Truvestments Capital
Florida
$4.71K -$2.96K -59 -40%
BHWM
257
Beaird Harris Wealth Management
Texas
$4.66K +$4.41K +88 New
WTA
258
Washington Trust Advisors
Massachusetts
$4.13K – – –
LJHT
259
Laurie J. Hall Trustee
$4K -$2.25K -45 -39%
FRA
260
Front Row Advisors
California
$4K – – –
PPC
261
Park Place Capital
Alabama
$4K +$3.56K +71 New
PWMG
262
Prestige Wealth Management Group
New Jersey
$2.22K +$2.1K +42 New
GRP
263
Global Retirement Partners
California
$2.12K – – –
CA
264
Centerpoint Advisors
Massachusetts
$2K – – –
MPWT
265
MassMutual Private Wealth & Trust
Connecticut
$2K – – –
Northwestern Mutual Wealth Management
266
Northwestern Mutual Wealth Management
Wisconsin
$1.85K +$1.75K +35 New
RCM
267
Raleigh Capital Management
North Carolina
$1.69K +$802 +16 +100%
NA
268
NewEdge Advisors
Louisiana
$1.59K +$1.5K +30 New
BAM
269
Bellevue Asset Management
Washington
$1.59K – – –
NC
270
NewSquare Capital
Pennsylvania
$1.06K +$1K +20 New
CPG
271
Cornerstone Planning Group
New Jersey
$908 +$952 +19 New
AAP
272
Arax Advisory Partners
Colorado
$847 – – –
BIA
273
Bell Investment Advisors
California
$794 – – –
VCM
274
Versant Capital Management
Arizona
$741 – – –
AWM
275
Accurate Wealth Management
Florida
$634 +$651 +13 New
9 10
11
12 13

ITCI Hedge Fund Activity: Q4 2022 in Review

283 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Intra-Cellular Therapies Inc. (ITCI) for Q4 2022, worth a combined $4.38B — up 14% from $3.85B a quarter earlier.

Buyers outnumbered sellers: 48 funds opened new ITCI positions and 36 closed out — a net gain of 12 holders — while 94 added to existing stakes and 94 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $88.1M. The largest seller was Lord, Abbett & Co, cutting an estimated $56.7M.

  • 283 institutional investors held Intra-Cellular Therapies Inc. (ITCI) as of Q4 2022, up from 274 in Q3 2022.
  • Funds reported $4.38B of Intra-Cellular Therapies Inc. stock for Q4 2022, up 14% quarter-over-quarter.
  • 48 funds opened new Intra-Cellular Therapies Inc. positions in Q4 2022 and 36 closed out, a net change of +12 holders.
  • The largest Intra-Cellular Therapies Inc. buyer in Q4 2022 was Fidelity Investments, an estimated $88.1M added.
  • The largest Intra-Cellular Therapies Inc. seller in Q4 2022 was Lord, Abbett & Co, an estimated $56.7M sold.

Based on aggregated 13F filings for Q4 2022.